NCT00520325View on ClinicalTrials.gov

A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and Neutropenia

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

August 31, 2009

Conditions
CancerHematologic DiseasesFeverNeutropenia
Interventions
DRUG

Intravenous recombinant human mannose binding lectin

Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

DRUG

Intravenous recombinant human mannose binding lectin

Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg

Sponsors
All Listed Sponsors
lead

Enzon Pharmaceuticals, Inc.

INDUSTRY